Skip to content
← All treatment topics

TREATMENT READING

Non-Hodgkin Lymphoma Treatment During Pregnancy (PDQ®)

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

Health professional

General Information About Non-Hodgkin Lymphoma Treatment During Pregnancy

Source: Non-Hodgkin Lymphoma Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 18, 2025. Captured 2026-09-09.

Non-Hodgkin lymphoma (NHL) is more common in older patients, with a median age at diagnosis of 68 years.[1] Hodgkin lymphoma is most common in early adulthood and in patients older than 65 years.[2] This age distribution may explain why there are fewer reports of NHL in pregnant patients.[3]

Sources: 1 · 2 · 3

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Treatment Option Overview for Non-Hodgkin Lymphoma During Pregnancy

Source: Non-Hodgkin Lymphoma Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 18, 2025. Captured 2026-09-09.

Table 1. Treatment Options for Non-Hodgkin Lymphoma (NHL) During Pregnancy
StageTreatment Options
Indolent NHL During PregnancyDelay treatment until after delivery
Aggressive NHL During PregnancyImmediate therapy
Early delivery, when feasible
Termination of pregnancy

Sources: Indolent NHL During Pregnancy · Aggressive NHL During Pregnancy · Immediate therapy · Early delivery, when feasible · Termination of pregnancy

Health professional

Treatment of Indolent Non-Hodgkin Lymphoma During Pregnancy

Source: Non-Hodgkin Lymphoma Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 18, 2025. Captured 2026-09-09.

Treatment may be delayed for women with an indolent non-Hodgkin lymphoma.

Health professional

Treatment of Aggressive Non-Hodgkin Lymphoma During Pregnancy

Source: Non-Hodgkin Lymphoma Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 18, 2025. Captured 2026-09-09.

Health professional · Treatment of Aggressive Non-Hodgkin Lymphoma During Pregnancy

Immediate Therapy

Source: Non-Hodgkin Lymphoma Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 18, 2025. Captured 2026-09-09.

According to anecdotal case series, most non-Hodgkin lymphomas (NHLs) in pregnant patients are aggressive, and delay of therapy until after delivery appears to have poor outcomes.[1-4] Consequently, some investigators favor immediate therapy, even during pregnancy.[4] In a review of 121 patient case reports from 74 papers, one-half of the patients had very aggressive lymphomas, such as Burkitt lymphoma, and one-half of the patients had involvement of the breast, ovaries, uterus, or placenta.[5] One-half of the patients received therapy antepartum, and the 6-month survival rate was 53%, with a live-birth rate of 83%.[5][Level of evidence C3]

Sources: 1 · 4 · 4 · 5 · 5 · Level of evidence C3

A multicenter retrospective analysis of 50 patients described pregnancy termination in 3 patients, deferral of therapy to postpartum in 15 patients (median 30 weeks gestation), and antenatal therapy in the remaining 32 patients (median 21 weeks gestation, all done after the first trimester).[6] With a median follow-up of 41 months, the 3-year progression-free survival rate was 53%, and the overall survival rate was 82%, using R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone) or modifications of this regimen.[6][Level of evidence C3]

Sources: 6 · 6 · Level of evidence C3

Health professional · Treatment of Aggressive Non-Hodgkin Lymphoma During Pregnancy

Early Delivery, When Feasible

Source: Non-Hodgkin Lymphoma Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 18, 2025. Captured 2026-09-09.

For some women, early delivery, when feasible, may minimize or avoid fetal exposure to chemotherapy or radiation therapy.

Health professional · Treatment of Aggressive Non-Hodgkin Lymphoma During Pregnancy

Termination of Pregnancy

Source: Non-Hodgkin Lymphoma Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 18, 2025. Captured 2026-09-09.

Termination of pregnancy in the first trimester may allow immediate therapy for women with aggressive NHL.

Health professional · Treatment of Aggressive Non-Hodgkin Lymphoma During Pregnancy

Effects of Treatment on Children

Source: Non-Hodgkin Lymphoma Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 18, 2025. Captured 2026-09-09.

Evidence (treatment effect on children exposed in utero):

With follow-up ranging from several months to 11 years, children who were exposed to high-dose doxorubicin-containing combination chemotherapy in utero (especially during the second and third trimester) had normal growth and no evidence of congenital malformations.[4,7-9] For most of the chemotherapeutic agents used for the treatment of NHL, there are no data regarding long-term effects on children exposed in utero.

Sources: 4 · 7 · 9

In one anecdotal case, a newborn exposed to a rituximab-containing regimen in utero was born with no circulating B lymphocytes. The newborn was otherwise healthy and recovered the circulating B lymphocytes by age 6 months with no unusual or persisting intercurrent infections.[10]

Sources: 10

For patients

Treatment of Non-Hodgkin Lymphoma During Pregnancy

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

For patients · Treatment of Non-Hodgkin Lymphoma During Pregnancy

Indolent Non-Hodgkin Lymphoma During Pregnancy

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

Women who have indolent (slow-growing) non-Hodgkin lymphoma during pregnancy may be treated with watchful waiting until after they give birth. (See the Treatment Options for Indolent Non-Hodgkin Lymphoma section for more information.)

Sources: indolent · non-Hodgkin lymphoma · pregnancy · watchful waiting · Treatment Options for Indolent Non-Hodgkin Lymphoma

For patients · Treatment of Non-Hodgkin Lymphoma During Pregnancy

Aggressive Non-Hodgkin Lymphoma During Pregnancy

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

Treatment of aggressive non-Hodgkin lymphoma during pregnancy may include the following:

Sources: aggressive · non-Hodgkin lymphoma · pregnancy

Treatment given right away based on the type of non-Hodgkin lymphoma to increase the mother's chance of survival. Treatment may include combination chemotherapy and rituximab.

Sources: survival · combination chemotherapy · rituximab

Early delivery of the baby followed by treatment based on the type of non-Hodgkin lymphoma.

If in the first trimester of pregnancy, medical oncologists may advise ending the pregnancy so that treatment may begin. Treatment depends on the type of non-Hodgkin lymphoma.

Sources: medical oncologists